Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.91% | 11.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.92% | 1.43% | |||
| Operating Income | -3.92% | -1.43% | |||
| Income Before Tax | 2.74% | 11.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.74% | 11.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.74% | 11.71% | |||
| EBIT | -3.92% | -1.43% | |||
| EBITDA | -3.95% | -1.54% | |||
| EPS Basic | 2.67% | 11.76% | |||
| Normalized Basic EPS | 2.98% | 11.65% | |||
| EPS Diluted | 2.67% | 11.76% | |||
| Normalized Diluted EPS | 2.98% | 11.65% | |||
| Average Basic Shares Outstanding | 0.00% | 0.01% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||